Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
about
Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmissionL-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virusAntibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesClosing the door to human immunodeficiency virus.Post-infection immunodeficiency virus control by neutralizing antibodiesHIV-1 infection of placental cord blood monocyte-derived dendritic cells.Which Antibody Functions are Important for an HIV Vaccine?Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroRhesus macaque dendritic cells efficiently transmit primate lentiviruses independently of DC-SIGNA Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnoverTransfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infectionVaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent.Modeling mucosal cell-associated HIV type 1 transmission in vitro.Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodiesBinding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway.Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection.Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaquesHIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting CellsThe Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
P2860
Q24537674-9E428730-5451-49C3-845D-779CCBCF8F72Q27473455-DD547F9F-D054-4929-8CF9-977E4EF5776DQ30408097-C6BC14F6-4793-4BE5-95C4-A8F8AF51EF10Q30428089-E3AEB5A6-63C1-49A7-9EB6-D794B2BC66F0Q33288264-AED43F23-569C-4F4D-AEEE-AA68526EE818Q33564810-F8949750-27E1-4F23-857F-71BB88708F7EQ33772637-E3FC5CE5-8B60-49E3-8B6A-0F03E05CAB07Q33826717-914AC48F-26C9-4E81-8871-A12AF6729DA9Q33843554-D1BF51E3-412D-44D7-BFC6-FAD3AF736BF5Q33853775-EC634D2B-A008-431B-BE68-C6BDF2D21BC5Q34010226-057E6D3C-EA2A-4BE4-88B6-731BFF8A8D4CQ34098868-AC6000E6-E2D0-43E1-B571-1ECC42E58418Q34349275-CEBB3C33-3EEB-4307-8638-D75571FDA649Q34391256-B5CA37B0-A9F3-41B8-80CE-A5086D0B854FQ34574462-7BBAF75C-9F28-40A4-97B9-47C6A3B2824EQ34786887-FC67C7CB-0431-4B77-9F8E-41B86B98824DQ35000072-2CA0B996-620B-4C60-A04E-D964CD297BB8Q35842299-09AC7C89-27BD-4769-BC9F-1815BB548CC4Q35849709-2D55C47C-922C-44C6-AB70-9E5BDB1EC8C5Q36525047-8ED22A2C-B32B-4ACA-BEE7-0B80280C81F1Q37059589-CD1BD874-A13E-446E-815E-384B49FD8128Q37145333-6767403F-F20A-4892-A138-61B0E4185F30Q37171570-BC62FAB5-6BF5-4916-AD1F-29FE4C743498Q37287774-AB8BA52A-5F80-43C8-81A0-D62A07DA0A86Q37415455-C945DAE4-70F0-419F-BF2B-5C0C57FD9390Q37583414-4400A4B7-F255-480F-A0B4-5F7D45FF89F4Q37730488-E400B5BA-5FB4-4DC7-BECB-6F59722E71CCQ39700360-F8EA014F-CDDD-425A-9F33-041BE8FB63D7Q57030223-AF67A96A-4889-47B7-A4DE-A97335D116C0
P2860
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@en
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@nl
type
label
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@en
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@nl
prefLabel
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@en
Neutralizing monoclonal antibo ...... s and transmission to T cells.
@nl
P2093
P2860
P1433
P1476
Neutralizing monoclonal antibo ...... ls and transmission to T cells
@en
P2093
D R Burton
H Katinger
J R Mascola
M K Louder
N Bhardwaj
N L Michael
P W Parren
R M Steinman
P2860
P304
P407
P577
1998-12-01T00:00:00Z